Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

e-Poster Display Session

233TiP - Pembrolizumab (pembro) or placebo added to docetaxel and prednisone/prednisolone for metastatic castration-resistant prostate cancer (mCRPC) previously treated with next-generation hormonal agents (NHAs): KEYNOTE-921 phase III study


22 Nov 2020


e-Poster Display Session


Tumour Site

Prostate Cancer


Daniel Petrylak


Annals of Oncology (2020) 31 (suppl_6): S1325-S1333. 10.1016/annonc/annonc369


D.P. Petrylak1, N.D. Shore2, M. Bennamoun3, R. Ratta4, J.M. Piulats5, B. Li6, C. Schloss6, K. Fizazi7

Author affiliations

  • 1 Internal Medicine, Smilow Cancer Hospital, Yale New Haven Health, 06520 - New Haven/US
  • 2 Urology, Carolina Urologic Research Center, 29572 - Myrtle Beach/US
  • 3 Medical Oncology, Institut Mutualiste Montsouris, 75014 - Paris/FR
  • 4 Medical Oncology, Hopital Foch, 92150 - Suresnes/FR
  • 5 Medical Oncology, Catalan Cancer Institute, 08902 - Barcelona/ES
  • 6 Medical Oncology, Merck & Co., Inc., 07033 - Kenilworth/US
  • 7 Medicine, Gustave Roussy, 94805 - Villejuif/FR


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 233TiP


Pembro is a humanized monoclonal antibody that binds to PD-1 and prevents interaction with its ligands, PD-L1 and PD-L2. In the KEYSTONE-365 phase Ib/II study (NCT02861573), pembro added to docetaxel + prednisone had antitumor activity for mCRPC after progression with abiraterone acetate/enzalutamide. The randomized, phase III KEYNOTE-921 study (NCT03834506) will be conducted to assess efficacy and safety of pembro vs placebo added to docetaxel + prednisone in patients with mCRPC whose disease progressed on NHAs and who have not received chemotherapy.

Trial design

Eligibility criteria include histologically or cytologically confirmed adenocarcinoma of the prostate without small cell histology; evidence of metastatic disease or PSA (PCWG3), soft tissue (RECIST v1.1), or bone (PCWG3) progression; prior treatment with 1 (but not more than 1) NHA (abiraterone acetate, enzalutamide, apalutamide, or darolutamide) for metastatic hormone-sensitive prostate cancer or CRPC (nonmetastatic or metastatic); ongoing androgen deprivation; and Eastern Cooperative Oncology Group performance status 0 or 1. Key exclusion criteria were prior treatment with docetaxel/other chemotherapy, therapeutic radiopharmaceutical agents, or other systemic therapies. Approximately 1000 enrolled patients will be randomly assigned 1:1 to receive pembro 200 mg or placebo Q3W (≤35 cycles) added to docetaxel 75 mg/m2 IV Q3W and prednisone 5 mg PO BID (≤10 cycles) until disease progression, unacceptable toxicity, or withdrawal. Response will be assessed using PCWG3-modified RECIST v1.1 by blinded independent central review (BICR) by imaging (CT/MRI/bone) Q9W through week 54 and then Q12W. The coprimary end points are OS and rPFS; additional details are in the table Table: 233TiP

End points in KEYNOTE-921

Primary Secondary
rPFS per PCWG3-modified RECIST v1.1, as assessed by BICR Confirmed PSA response ratea
ORR and DOR per PCWG3-modified RECIST v1.1, assessed by BICR
Time to PSA progression
Time to first symptomatic skeletal-related event
Time to pain progression based on BPI (SF) item 3 and on opioid analgesic use based on the analgesic quantification algorithm score
Safety and tolerability

aDecrease of ≥50% from baseline, measured twice ≥3 weeks apart.


Clinical trial identification

NCT03834506, February 8, 2019.

Legal entity responsible for the study

Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.


Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.


D.P. Petrylak: Advisory/Consultancy: Ada Cap (Advanced Accelerator Applications) Amgen, Astellas, AstraZeneca, Bayer, Bicycle Therapeutics, Boehringer Ingelheim, Bristol-Myers Squibb, Clovis Oncology, Eli Lilly, Exelixis, Incyte, Janssen, Mirati, Monopteros, Pfizer, Pharmacyclics, Roche, Sea; Shareholder/Stockholder/Stock options, Sold 10/2019: Bellicum, Tyme; Research grant/Funding (institution), *Denotes study trials that have terminated: Ada Cap (Advanced Accelerator Applications), Agensys Inc, *Astellas, AstraZeneca, *Bayer, BioXcel Therapeutics, Bristol-Myers Squibb, Clovis Oncology, Eisai, *Eli Lilly, *Endocyte, Genentech, *Innocrin, MedImmune, Medivation, Merck, Mirati, *Novartis, Pfi. N.D. Shore: Advisory/Consultancy, Travel/Accommodation/Expenses: Amgen, Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Dendreon, Ferring, Fergene, Janssen, Merck, MDxHealth, Myovant, Nymox, Pfizer, Sanofi-Genzyme, Tolmar; Speaker Bureau/Expert testimony: Bayer, Janssen, Pfizer, Astellas; Leadership role, Immediate Past President: LUGPA. R. Ratta: Advisory/Consultancy: Astellas. J.M. Piulats: Advisory/Consultancy: Roche, Novartis, Jansen, Astellas, Bayer, Sanofi-Genzyme, MSD, Bristol-Myers Squibb, Merk-Serono, Clovis, AstraZeneca, Beigene, VCN Biotech; Research grant/Funding (self): Roche, Jansen, Astellas, MSD, Bristol-Myers Squibb, Merk-Serono, AstraZeneca, Beigene, VCN Biotech; Travel/Accommodation/Expenses: Roche, Astellas, Jansen. B. Li: Full/Part-time employment: MSD R&D (China) Co., Ltd. C. Schloss: Shareholder/Stockholder/Stock options, Full/Part-time employment: Merck & Co., Inc. K. Fizazi: Advisory/Consultancy: Amgen, Janssen, Sanofi, Astellas, Orion, MSD, Bayer. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.